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Genetically derived hematologic cytopenias are a rare heterogeneous group of disorders. Allogeneic hemato-
poietic cell transplantation (HCT) is curative but offset by organ toxicities from the preparative regimen, graft
rejection, graft-versus-host disease (GVHD), ormortality. Becauseof thesepossibilities, considerationofHCTcan
be delayed, especially in the unrelated donor setting. We report a prospective multicenter trial of reduced-
intensity conditioning (RIC) with alemtuzumab, ﬂudarabine, and melphalan and HCT in 11 children with
marrow failure of genetic origin (excluding Fanconi anemia) using the best available donor source (82% from
unrelated donors). Themedian age at transplantationwas 23months (range, 2months to 14 years). Themedian
times to neutrophil (>500  106/L) and platelet (>50  109/L) engraftment were 13 (range, 12 to 24) and 30
(range, 7 to 55) days, respectively. The day þ100 probability of grade II to IV acute GVHD and the 1-year
probability of limited and extensive GVHD were 9% and 27%, respectively. The probability of 5-year overall
and event-free survival was 82%; 9 patients were alive with normal blood counts at last follow-up and all were
successfully off systemic immunosuppression. In patients with genetically derived severe hematologic cyto-
penias, allogeneic HCT with this RIC regimen was successful in achieving a cure. This experience supports
consideration of HCT early in such patients even in the absence of suitable related donors.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION at a young age before the increasing risks associated with
Hematologic cytopenias due to bone marrow dysfunction
(BMD) of genetic etiology include a heterogeneous group of
disorders where genetic mutations result in abnormal or
arrested hematopoiesis affecting 1 or more cell lines [1-3].
Conservative management of a lifelong defect in hematopoi-
esis is challenging and includes chronic transfusion therapy
with inherent risks of infection, iron overload, anemia,
bleeding, alloimmunization, susceptibility to life-threatening
infections, and in many BMD, a predisposition to malignant
transformation, usually acute myeloid leukemia [4-8].
Allogeneic hematopoietic cell transplantation (HCT) can
cure the hematopoietic defects associated with BMD. The
heterogeneity of BMD and associated organ involvement in
some disorders present unique obstacles to successful HCT.
In addition, the challenges of allogeneic transplantation,
including identiﬁcation of a suitable donor and optimization
of preparative therapy to reduce regimen-related toxicity
while ensuring successful engraftment, are important to
overcome. Low rates of mortality, graft-versus-host disease
(GVHD), and untoward late effects from HCT will promote
consideration of transplantation earlier for BMD [9]. Safe and
effective transplantation methods are a key to promoting
long-term survival and maintaining quality of life after HCTdgments on page 1325.
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15.03.019conservative management of the marrow failure. Many BMD
are associated with defective DNA repair or maintenance
pathways and possess increased sensitivity to DNA-
damaging agents, including chemotherapy and radiation.
These sensitivities have resulted in increased HCT-related
morbidity and mortality in BMD patients [2,9]. Further, the
presence of genetic predisposition to malignant trans-
formation requires development of transplantation ap-
proaches that minimize additional risks of late malignancies,
which makes reduced-intensity conditioning (RIC) regimen
an appealing choice.
Trials of HCT after RIC have recently targeted several
groups of recipients for reasons such as age and pre-existing
organ toxicity. Although RIC regimens are perhaps better
tolerated, barriers to using RIC regimens and proceeding
with HCT include risk of GVHD from unrelated donor grafts
and potentially increased rates of graft rejection, especially in
the immune competent and those exposed to multiple blood
products [10].
This study describes the outcomes of a prospective,
pediatric, multicenter, phase II HCT trial for children with
BMD who had undergone RIC to achieve signiﬁcant host
immunosuppression. The primary objective was to deter-
mine donor engraftment, overall survival (OS), and event-
free survival (EFS) after conditioning with alemtuzumab,
ﬂudarabine, and melphalan and HCT from the best avail-
able donor in patients with BMD and severe hematologic
cytopenia. Fanconi anemia patients were excluded because
of the use of the alkylating agent melphalan in the regimen
and the unknown toxicity imparted by this drug on
affected patients. Secondary objectives were to evaluate for
A. Kothari et al. / Biol Blood Marrow Transplant 21 (2015) 1315e13361322immune reconstitution, infection, and transplantation-
related toxicities.
METHODS
Patient and Donor Selection
BMD patients were enrolled at 4 transplantation centers. The protocol
was approved by the institutional review board at each of the participating
institutions (NCT00920972). Consent was obtained from legal guardians of
all patients before enrollment and assents were obtained when appropriate.
Eligibility included patients younger than 21 years of age with a diagnosis of
a BMD other than Fanconi anemia. Patients with human immunodeﬁciency
virus seropositivity, Lansky performance score  50, or uncontrolled active
bacterial, viral, or fungal infections were ineligible.
Donors were selected based upon the best allele match for HLA-A, HLA-
B, HLA-C, and DRB1 by high-resolution typing. In the absence of matched
related donor (MRD) marrow, 7 to 8/8 allele/antigen matched unrelated
donor (URD) marrow was considered eligible. Umbilical cord blood (UCB)
products were required to be matched at a minimum of 4 of 6 HLA loci (low
resolution at A and B; high resolution at DRB1) and have a pre-
cryopreservation total nucleated cell number of  4.0  107 per kilogram
recipient weight. Marrow products were infused fresh and unmanipulated
except as required for ABO incompatibility between donor and recipient.
Conditioning Regimen and GVHD Prophylaxis
All patients received alemtuzumab intravenously (i.v.) daily for 3 days
(10 mg, 15 mg, and 20 mg if >10 kg and 10 mg on each day if  10 kg)
between day 21 and 19 after a 3 mg test dose per manufacturer rec-
ommendations on day 22. The total dose of alemtuzumab was 48 mg in
children >10 kg and 33 mg in children  10 kg. Patients were discharged
after alemtuzumab administration and readmitted on day 8. Fludarabine
(30 mg/m2 or 1 mg/kg if  10 kg) was administered i.v. daily between
days 8 and 4. Melphalan (140 mg/m2 or 4.7 mg/kg if  10 kg) was
administered i.v. on day 3 [11]. GVHD prophylaxis consisted of cyclo-
sporine or tacrolimus and short-course methotrexate (7.5 mg/m2 on days 1,
3, and 6). Cyclosporine or tacrolimus was started on day 3 with regular
monitoring to maintain therapeutic levels, continued to day þ100, and
tapered gradually to stop by day þ180 in the absence of GVHD. In addition,
prednisone was administered to all unrelated bone marrow (URD BM) re-
cipients at 1mg/kg/day from dayþ7 toþ28 and subsequently tapered in the
absence of GVHD. UCB recipients received a calcineurin inhibitor and
mycophenolate mofetil (MMF) instead. MMF (1 g every 8 hours for children
 50 kg or 15 mg/kg every 8 hours for children< 50 kg) was commenced on
day -3 and continued through day þ45 or for 7 days after engraftment,
whichever came later. MMF levels were not monitored.
Supportive Care
All patients received antibiotic prophylaxis with oral ciproﬂoxacin,
itraconazole (until day 100 for BM and day 180 for UCB), acyclovir (until
1 year if herpes simplex virus or varicella zoster virus positive) andTable 1
Patient Characteristics and Outcomes
Patient No. Diagnosis (Indication for Transplantation) Age at HCT,
mo/gender
1 CDA Type 1 (Red cell transfusion dependent) 23/M
2 DBA (transfusion dependent since 7 weeks of
life - unresponsive to steroids)
12/F
3 SDS (pancytopenia) 168/F
4 Congenital BMD (red cell and platelet transfusion
dependent since birth) [31]
2/M
5 CAMT (platelet transfusion dependent) 12/M
6 X-linked thrombocytopenia (platelet transfusion
dependent from 1 mo. of life)
12/M
7 DBA (transfusion dependent since infancy
-unresponsive to steroids)
72/M
8 CAMT (platelet transfusion dependent) 36/M
9 SCN (severe neutropenia) 156/M
10 X-linked thrombocytopenia (platelet transfusion
dependent)
14/M
11 DBA (transient response to steroids; recurrence with
myeloﬁbrosis at 2.5 years)
34/M
TNC indicates total nucleated cells; cGVHD, chronic graft versus host disease; FU, fo
M, male; A & W, alive and well; SDS, Shwachman Diamond syndrome; F, fe
thrombocytopenia.trimethoprim-sulfamethoxazole (until 1 year) after engraftment. Patients
were monitored weekly for cytomegalovirus (CMV) and Epstein-Barr virus
(EBV) DNA until day þ100. If CMV was detected, pre-emptive ganciclovir or
foscarnet (if before engraftment) therapy was administered until CMV
testing was negative  2. Patients received transfusion of red blood cells if
their hemoglobin levels fell below 70 g/L. Platelet transfusions were given
for levels below 20  109/L. Granulocyte colonyestimulating factor at a dose
of 5 mg/kg/day was commenced on day þ7 and was continued until the
absolute neutrophil count was greater than .5109/L for 3 consecutive days.Endpoints/Statistical Evaluation
Primary endpoints were engraftment, OS, and EFS. Neutrophil engraft-
ment was deﬁned as the ﬁrst of 3 consecutive days with an absolute
neutrophil count greater than 500/mL, and platelet recovery was deﬁned as
the ﬁrst of 7 consecutive days of a platelet count greater than or equal to
50,000/mL without a transfusion. Donor engraftment was determined by
demonstrating chimerism by short tandem repeat analysis in BM and/or
peripheral blood. The percentage of donor chimerismwas assessed at 1, 3, 6,
9, and 12 months after HCT in the ﬁrst year, every 6 months in the second
year, and yearly thereafter. Formal assessments of immunologic recovery
were made on days þ100 and þ180 and 12 months after HCT. Lymphocyte
subpopulations were measured using ﬂow cytometry to calculate absolute
lymphocyte count, CD3, CD4, CD8, CD19, and CD16 þ 56 cell numbers.
Immunoglobulin levels (IgG, IgA, and IgM) were measured at the same
intervals.
Statistical analyses were performed in Prism 5.03 (GraphPad, La Jolla,
CA). The cutoff date for analysis was April 30, 2014. Continuous variables
were summarized as medians and range and categorical variables as per-
centages. Cumulative incidence of neutrophil and platelet engraftment at
21 days, acute GVHD (aGVHD) at dayþ100 and chronic GVHD at 1 year were
all estimated. OS, EFS, and treatment-related mortality were estimated us-
ing Kaplan-Meier estimators and comparisons between groups (MRD and
URD) were carried out. P values less than .05 were considered signiﬁcant.RESULTS
Patient Characteristics
Eleven patients between 2 months and 14 years (median,
23 months) with BMDwere enrolled in this study of RIC HCT.
Patients, diagnoses, indication for transplantation, trans-
plantation characteristics, and outcomes are summarized in
Table 1. Nine were recipients of URD HCT. BM was the source
of hematopoietic stem cells in all but 1 patient who received
4 of 6 matched UCB. The median total nucleated and CD34þ
cells per kg were 4.1108 (range, .98 108 to 7.92108) and
4.36  106 (range, .6  106 to 8.82  106), respectively.Follow- up,
yr
Donor
Source
HLA
Match
TNC,
per kg
(108)
CD34,
per kg
(106)
aGVHD/
cGVHD
Outcome/On
or Off IS at
Last FU
10 URD UCB 4/6 .98 .6 0/0 A & W/off
8 URD BM 8/8 4.92 2.41 0/0 A & W/off
45 days URD BM 8/8 3.8 4.2 Gr 4/NE Died/on
6 MSD BM 8/8 5.8 7.8 0/0 A & W/off
5 URD BM 8/8 3.95 4.82 0/0 A & W/off
7 URD BM 8/8 5.14 8.82 Gr 3/0 A & W/off
6 MSD BM 8/8 3.64 5.2 0/0 A & W/off
3.5 URD BM 8/8 3.5 3.31 0/0 A & W/off
1.5 URD BM 8/8 4.1 3.68 0/0 A & W/off
1.2 URD BM 8/8 7.92 5.92 0/0 A & W/off
1 URD BM 8/8 7.41 4.36 Gr 4/NE Dead/NE
llow-up; IS, immunosuppression; CDA, congenital dyserythropoeitic anemia;
male; Gr, grade; NE, not evaluable; CAMT, congenital amegakaryocytic
Figure 1. Probability of OS and EFS. (A) Five-year overall survival: 82% (95% CI,
52.3% to 94.9%) and (B) 5-year event-free survival: 82% (95% CI, 52.3% to 94.9%)
after hematopoietic cell transplantation for inherited bone marrow failure
syndromes. Events were deﬁned as graft rejection, persistent hematologic
cytopenias, or death. Dots depict a censored event.
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At a median follow-up of 62 months (range, 12 to 186
months), 9 of the 11 recipients had stably engrafted donor
cells and had normal blood counts. The probability of EFS and
OS at 5 years was 82% (Figure 1A,B). The cumulative inci-
dence of neutrophil recovery was 91% on day 21 and the
median time to neutrophil engraftment was 13 days (range,
12 to 24 days). The cumulative incidence of platelet recovery
(>50  109/L) was 73% on day 30 and the median time to
recovery was 19 days (range, 7 to 55 days). The recipient who
succumbed to aGVHD did not achieve platelet recovery. Each
patient had >95% donor chimerism by short tandem repeat
analysis in either BM cells or T lymphoid (CD3) and myeloid
(CD15) compartments of peripheral blood each time, except
for patient 11 (Table 1), who had graft rejection on day 180.Acute and Chronic GVHD
At 100 days after HCT, the cumulative incidence of grade II
to IV aGVHD was 9%.
Two patients with aGVHD died after additional compli-
cations as described below. At 180 days after HCT, the cu-
mulative incidence of GVHD was 27%. In addition to the
2 deaths, 1 patient developed grade III skin and gut acVHD
that resolved with intensiﬁcation of immunosuppression. All
surviving patients were weaned off immunosuppression by
2 years after HCT (Table 1).Figure 2. Serial immune reconstitution studies. Serial immune reconstitution show
numbers of lymphocyte subsets (median and range) CD3, CD4, CD8, and CD19 on da
(median and range) on days 100, 180, and 365 after transplantation. Shaded areas reImmune Reconstitution
Absolute numbers of CD3þ, CD4þ, CD8þ T cells, and B cells
showed recovery after day þ180 and were in the normal
range by 1 year (Figure 2A). Serum concentrations of im-
munoglobulins (IgA, IgM and IgG) remained at the lower
limits of normal during the ﬁrst year (Figure 2B). The con-
centration of IgG fell during the ﬁrst year and was the lowest
of all immunoglobulin levels (Figure 2B), presumably
because of alemtuzumab-induced donor B cell depletion
despite early administration of the agent.
Infections
Infectious complications were common in the ﬁrst
6monthsandgraduallydecreased in frequency inconcertwith
immunologic recovery. During the ﬁrst 100 days, 6 patients
had bacteremia with organisms including coagulase-negative
Staphylococcus, methicillin-resistant Staphylococcus aureus,
S. maltophilia, and S. pneumoniae. One patient developed a
urinary tract infection (UTI) and another had Clostridium
difﬁciledetected in stool. Viral infections in 4 patients included
CMV and EBV replication, adenovirus, rhinovirus, varicella,
and human herpes virus 6. CMV reactivation occurred in 1 of 3
patients who were at high risk for reactivation (donor sero-
positive/seronegative, recipient seropositive). EBV replication
was asymptomatic and not treated; no patient progressed to
post-transplantation lymphoproliferative disease. Between
100 and 180 days, 4 patients had bacteremia with coagulase-
negative Staphylococcus, E. faecalis, and E. gergoviae, 1 had a
UTI with K. pneumoniae, and 2 viral infections (CMV reac-
tivation and parainﬂuenza) were noted. Between 180 and 365
days, 2 patients had bacteremia and another had an E. col-
iederived UTI. No fungal infections were observed in any
patients.
Mortality
One patient with Diamond Blackfan anemia (DBA with
subsequent myeloﬁbrosis) had graft rejection on day 180
(after initial engraftment). Restrictive pulmonary disease
(presumed bronchiolitis obliterans either due to the under-
lying disease or GVHD) was noted during the 6 month
follow-up period and treated symptomatically. A second
(myeloablative) transplantationwas performed on dayþ346,
but he died 10 days later of progressive respiratory failure.
Another recipient with Shwachman Diamond syndrome dieding gradual recovery with time in lymphocyte subset numbers. (A) Absolute
ys 100, 180 and 365 after transplantation. (B) Immunoglobulin concentrations
present the normal values.
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day þ45 (Table 1).
DISCUSSION
Although allogeneic HCT reverses the cytopenias of BMD,
a key obstacle to contemplating the same early in patients
with symptomatic BMD is the risk of mortality, treatment-
related toxicities, and GVHD. These side effects are more
likely in the absence of suitable matched family donors. This,
as well as disease-related factors, such as organ involvement,
exposure to transfusions, iron overload, underlying in-
fections, and bleeding risks, compound the risks of trans-
plantation toxicity and graft rejection [9]. Hence, HCT reports
on large numbers of patients with BMD are scarce. Patients
with many forms of BMD, including DBA, dyskeratosis con-
genita, severe congenital neutropenia, and congenital ame-
gakaryocytic thrombocytopenia, have an increased risk of
eventual clonal malignant transformation in the hemato-
poietic cells [5-8,12]. Avoiding the use of high-dose chemo-
therapy or radiation to achieve successful allogeneic donor
cell engraftment is beneﬁcial in this situation. The hypothesis
for this study was based on substitution of myeloablation
with recipient immunoablation in the preparative regimen
to achieve donor cell engraftment irrespective of donor
source (MRD or URD).
Previous studies have reported on HCT after myeloa-
blative regimens with moderate success but with room for
improvement. A registry report on outcomes of 61 patients
transplanted for DBA was associated with a mortality rate of
18%. The OS was higher for MRD compared to that for URD
(78% versus 45% at 1 year, and 76% versus 39% at 3 years,
respectively). The majority of transplants (67%) in this report
were from MRD [10]. Zeidler et al. reported on HCT in 11
patients with severe congenital neutropenia (SCN) before
malignant transformation. Eight received MRD grafts, and 2
of the 3 alternate donor transplant recipients did not survive.
OS aftermyeloablative regimenswas 80% at amedian follow-
up of 10 months [13]. The French SCN registry reported HCT
outcomes on 5 SCN patients before malignant trans-
formation. All received myeloablative regimens with 80%
engraftment and 40% mortality due to infection at 1-year
after transplantation [14]. Bizzetto et al., on behalf of Euro-
pean Society for Blood and Marrow Transplantation, re-
ported 95% OS at 3 years after related UCBT but only 61% OS
after URD UCBT for hereditary BM failure syndromes other
than Fanconi anemia [15].
An alemtuzumab-based immunosuppressive RIC regimen
was successful in achieving donor cell engraftment in chil-
dren with transfusion-dependent BMD enrolled on this trial.
Survival and cure rates were high (82%) and comparable or
better than previous reports. Although the number of pa-
tients reported is small, the majority underwent URD, which
can be deferred in BMD patients for reasons of toxicity. This
regimen provides an opportunity to lower the intensity and
deliver HCT to this group of patients who otherwise have a
signiﬁcant risk of morbidity and mortality [12]. The follow-
up period is relatively short and long-term tracking for the
incidence of late effects including malignancy are in prog-
ress. Our experience with this group of BMD mirrors the
successful experience previously reported in 7 patients who
underwent transplantation for marrow failure with
Shwachman Diamond syndrome using a similar regimen,
none of which are included in this group [16]. Of note, only
1 patient in this current series received an UCB graft and had
a good outcome. This experience is inadequate to determinewhether this regimen is adequate to achieve donor engraft-
ment with UCB transplantations and should be used with
caution given the high rate of graft rejection described with
UCB in other nonmalignant disorders [17].
The incidence of grade II to IV aGVHD at day þ100 was
low (9%) despite the predominance of URD transplantations.
This compares favorably with previous reports that have
cited a day þ100 incidence of grade II to IV aGVHD of 24%
[15]. This could perhaps be attributed to the use of
T-depleting monoclonal antibody during conditioning and
the young recipient age. The timing of alemtuzumab
administration, however, was intentionally distal to the time
of transplantation to achieve better recipient immunosup-
pression (to facilitate engraftment) at the expense of signif-
icant T cell depletion of the graft (to offset GVHD). The overall
incidence of GVHD in this report is consistent with other
reports of HCT using alemtuzumab [18,19]. Alemtuzumab, an
antibody against CD52, not only effectively depletes T and
B cells but also eliminates a subset of dendritic cells involved
in antigen presentation [20]. GVHD incidence from previous
reports on BMD transplantations range from 26% to 53%
[10,15]. Though 27% in this report developed GVHD in the
ﬁrst year, it was encouraging that all surviving recipients
were off immunosuppression without GVHD recurrence by
2 years after HCT. GVHD prophylaxis was weaned between
3 and 6 months in the absence of GVHD.
Withdrawal of immunosuppression and cellular immune
reconstitution predictably paralleled each another
(Figure 2A). Infections are to be expected with immunosup-
pressive T celledepleting regimens and were encountered
early in this group [21,22]. Patients were strictly ineligible to
proceed to transplantation in the presence of invasive in-
fections. No infection-related mortality was encountered,
though multiple infections were documented; more in the
ﬁrst 6 months than the latter part of the ﬁrst year. However,
we believe that the timing of the alemtuzumab avoided
delayed immune reconstitution and late infectious compli-
cations. CMV reactivation (33% in our series; no CMV disease)
is anticipated in at-risk patients; rates as high as 50% to 85%
are previously described [23,24]. Careful surveillance for viral
reactivation with pre-emptive targeted therapy is strongly
recommended until immune reconstitution and subsidence
of lymphopenia. In contrast to standard practice, pre-emptive
therapy forCMVreactivationwas institutedat thedetectionof
CMV replication, however trivial. Immune reconstitution
studies were helpful in determining patterns of lymphocyte
depletion and recovery. This was tracked carefully due to
delayed immune reconstitution and risk for late infections
with the peritransplantation use of alemtuzumab [21,23,25-
27]. Tracking lymphocyte subpopulations was helpful in
predicting infection risks and highlighted the need for very
close monitoring before 6 months after HCT (Figure 2). The
pace of immune reconstitutionwas robust after 6months and
matched thatnotedafterHCTwithout Tcell depletion, despite
the use of a lymphodepleting antibody [28-30]. Immuno-
globulin levels, however, were the last to recover.
In conclusion, this multicenter prospective study, utiliz-
ing an alemtuzumab-based RIC was effective in achieving
favorable outcomes after HCT in children with BMD. This
novel approach provided adequate host immune suppres-
sion to support engraftment with acceptable rates of GVHD
and treatment-related mortality. Although the study
included a small group of patients, the favorable results for
this rare group of disorders support a consideration of
transplantation early in this young population before the
A. Kothari et al. / Biol Blood Marrow Transplant 21 (2015) 1315e1336 1325development of serious marrow-related sequelae in those
severely afﬂicted.
ACKNOWLEDGMENTS
This work was supported by the St. Louis Children’s
Hospital Foundation.
Financial disclosure: The authors have no ﬁnancial dis-
closures to report.
Conﬂict of interest statement: There are no conﬂicts of in-
terest to report.
REFERENCES
1. Sieff CA, Nisbet-Brown E, Nathan DG. Congenital bone marrow failure
syndromes. Br J Haematol. 2000;111:30-42.
2. Alter BP. Bone marrow failure syndromes in children. Pediatr Clin N Am.
2002;49:973-988.
3. Myers KC, Davies SM. Hematopoietic stem cell transplantation for bone
marrow failure syndromes in children. Biol Blood Marrow Transplant.
2009;15:279-292.
4. Donadieu J, Leblanc T, Bader Meunier B, et al. Analysis of risk factors for
myelodysplasias, leukemias and death from infection among patients
with congenital neutropenia. Experience of the French Severe Chronic
Neutropenia Study Group. Haematologica. 2005;90:45-53.
5. Rosenberg PS, Alter BP, Link DC, et al. Neutrophil elastase mutations
and risk of leukaemia in severe congenital neutropenia. Br J Haematol.
2008;140:210-213.
6. Alter B, Giri N, Savage S, Rosenberg P. Cancer in dyskeratosis congenita.
Blood. 2009;113:6549-6557.
7. Alter B, Giri N, Savage S, et al. Malignancies and survival patterns in the
National Cancer Institute inherited bone marrow failure syndromes
cohort study. Br J Haematol. 2010;150:179-188.
8. Vlachos A, Rosenberg P, Atsidaftos E, et al. Incidence of neoplasia in
Diamond Blackfan anemia: a report from the Diamond Blackfan Ane-
mia Registry. Blood. 2012;119:3815-3819.
9. MacMillan ML, Wagner JE. Hematopoietic cell transplantation for
congenital bone marrow failure. Curr Opin Oncol. 2005;17:106-113.
10. RoyV, PerezWS,EapenM,etal. Bonemarrowtransplantation fordiamond-
blackfan anemia. Biol Blood Marrow Transplant. 2005;11:600-608.
11. Shenoy S, Grossman WJ, DiPersio J, et al. A novel reduced-intensity
stem cell transplant regimen for nonmalignant disorders. Bone
Marrow Transplant. 2005;35:345-352.
12. Morimoto K, Moore TB, Schiller G, Sakamoto KM. Transplantation for
congenital bone marrow failure syndromes. Bone Marrow Res. 2011;
2011:849387.
13. Zeidler C, Welte K, Barak Y, et al. Stem cell transplantation in patients
with severe congenital neutropenia without evidence of leukemic
transformation. Blood. 2000;95:1195-1198.
14. Ferry C, Ouachee M, Leblanc T, et al. Hematopoietic stem cell trans-
plantation in severe congenital neutropenia: experience of the French
SCN register. Bone Marrow Transplant. 2005;35:45-50.
15. Bizzetto R, Bonﬁm C, Rocha V, et al. Outcomes after related and un-
related umbilical cord blood transplantation for hereditary bone
marrow failure syndromes other than Fanconi anemia. Haematologica.
2011;96:134-141.
16. Bhatla D, Davies SM, Shenoy S, et al. Reduced-intensity conditioning is
effective and safe for transplantation of patients with Shwachman-
Diamond syndrome. Bone Marrow Transplant. 2008;42:159-165.17. Kamani NR, Walters MC, Carter S, et al. Unrelated donor cord blood
transplantation for children with severe sickle cell disease: results of
one cohort from the phase II study from the Blood and Marrow
Transplant Clinical Trials Network (BMT CTN). Biol Blood Marrow
Transplant. 2012;18:1265-1272.
18. Styczynski J, Tallamy B, Waxman I, et al. A pilot study of reduced
toxicity conditioning with BU, ﬂudarabine and alemtuzumab before
the allogeneic hematopoietic SCT in children and adolescents. Bone
Marrow Transplant. 2011;46:790-799.
19. Law J, Cowan MJ, Dvorak CC, et al. Busulfan, ﬂudarabine, and alemtu-
zumab as a reduced toxicity regimen for children with malignant and
nonmalignant diseases improves engraftment and graft-versus-host
disease without delaying immune reconstitution. Biol Blood Marrow
Transplant. 2012;18:1656-1663.
20. Ratzinger G, Reagan JL, Heller G, et al. Differential CD52 expression
by distinct myeloid dendritic cell subsets: implications for alem-
tuzumab activity at the level of antigen presentation in allogeneic
graft-host interactions in transplantation. Blood. 2003;101:
1422-1429.
21. Chakrabarti S, Collingham KE, Marshall T, et al. Respiratory virus in-
fections in adult T cell-depleted transplant recipients: the role of
cellular immunity. Transplantation. 2001;72:1460-1463.
22. Novitzky N, Rouskova A. Infectious complications following T-cell
depleted hematopoietic stem-cell transplantation. Cytotherapy. 2001;
3:165-173.
23. Chakrabarti S, Mackinnon S, Chopra R, et al. High incidence of cyto-
megalovirus infection after nonmyeloablative stem cell trans-
plantation: potential role of Campath-1H in delaying immune
reconstitution. Blood. 2002;99:4357-4363.
24. Vassiliou GS, Webb DK, Pamphilon D, et al. Improved outcome of
alternative donor bone marrow transplantation in children with severe
aplastic anaemia using a conditioning regimen containing low-dose
total body irradiation, cyclophosphamide and Campath. Br J Haema-
tol. 2001;114:701-705.
25. Avivi I, Chakrabarti S, Milligan DW, et al. Incidence and outcome of
adenovirus disease in transplant recipients after reduced-intensity
conditioning with alemtuzumab. Biol Blood Marrow Transplant. 2004;
10:186-194.
26. D’Sa S, Peggs K, Pizzey A, et al. T- and B-cell immune reconstitution
and clinical outcome in patients with multiple myeloma receiving T-
cell-depleted, reduced-intensity allogeneic stem cell transplantation
with an alemtuzumab-containing conditioning regimen followed by
escalated donor lymphocyte infusions. Br J Haematol. 2003;123:
309-322.
27. van Besien K, Dew A, Lin S, et al. Patterns and kinetics of T-cell
chimerism after allo transplant with alemtuzumab-based conditioning:
mixed chimerism protects from GVHD, but does not portend disease
recurrence. Leuk Lymphoma. 2009;50:1809-1817.
28. Atkinson K. Reconstruction of the haemopoietic and immune systems
after marrow transplantation. Bone Marrow Transplant. 1990;5:
209-226.
29. Fujimaki K, Maruta A, Yoshida M, et al. Immune reconstitution assessed
during ﬁve years after allogeneic bone marrow transplantation. Bone
Marrow Transplant. 2001;27:1275-1281.
30. Fallen PR, McGreavey L, Madrigal JA, et al. Factors affecting
reconstitution of the T cell compartment in allogeneic haemato-
poietic cell transplant recipients. Bone Marrow Transplant. 2003;32:
1001-1014.
31. Castillo-Caro P, Dhanraj S, Haut P, et al. Proximal radio-ulnar synostosis
with bone marrow failure syndrome in an infant without a HOXA11
mutation. J Pediatr Hematol Oncol. 2010;32:479-485.
